Analyst Reco. Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
34.58 ^USD	+2.73%		+9.19%	+55.28%

May. 02	Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss	MT
May. 02	Transcript : Agios Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Trims Price Target on Agios Pharmaceuticals to $42 From $43, Keeps Outperform Rating	Feb. 16	MT
Goldman Sachs Adjusts Price Target on Agios Pharmaceuticals to $28 From $32, Maintains Neutral Rating	Nov. 03	MT
JPMorgan Adjusts Agios Pharmaceuticals' Price Target to $32 From $33, Keeps Neutral Rating	23-08-07	MT
RBC Lifts Price Target on Agios Pharmaceuticals to $42 From $40 as Phase 2 Trial of Sickle Cell Disease Treatment Meets Primary Endpoint; Outperform Kept	23-06-27	MT
Piper Sandler Starts Agios Pharmaceuticals at Overweight With $41 Price Target	23-02-03	MT
JPMorgan Chase Adjusts Price Target on Agios Pharmaceuticals to $33 From $48, Maintains Neutral Rating	22-12-01	MT
Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral from Sell, Lifts Price Target to $32 From $17	22-11-17	MT
RBC Trims Price Target on Agios Pharmaceuticals to $43 From $44, Maintains Outperform Rating	22-11-04	MT
RBC Cuts Price Target on Agios Pharmaceuticals to $44 From $48, Maintains Outperform Rating	22-08-05	MT
SVB Securities Upgrades Agios Pharmaceuticals to Outperform from Market Perform, Keeps $33 Price Target	22-07-27	MT
RBC Lifts Price Target on Agios Pharmaceuticals to $48 From $47, Maintains Outperform Rating	22-07-07	MT
Goldman Sachs Adjusts Agios Pharmaceuticals' Price Target to $16 from $20, Keeps Sell Rating	22-05-24	MT
SVB Securities Adjusts Price Target for Agios Pharmaceuticals to $33 From $30, Maintains Market Perform Rating	22-05-17	MT
RBC Cuts Price Target on Agios Pharmaceuticals to $47 From $67, Maintains Outperform Rating	22-05-06	MT
HC Wainwright Lowers Agios Pharmaceuticals Price Target to $96 From $98, Maintains Buy Rating	22-03-03	MT
RBC Raises Price Target on Agios Pharmaceuticals to $67 From $61, Maintains Outperform Rating	22-02-25	MT
SVB Leerink Adjusts Agios Pharmaceuticals' Price Target to $30 from $32, Maintains Market Perform Rating	22-02-22	MT
HC Wainwright Adjusts Agios Pharmaceuticals' Price Target to $98 from $95, Keeps Buy Rating	22-02-18	MT
Canaccord Genuity Adjusts Agios Pharmaceuticals' Price Target to $44 from $52, Maintains Buy Rating	22-02-16	MT
Canaccord Genuity Adjusts Agios Pharmaceuticals' Price Target to $52 From $65, Keeps Buy Rating	21-12-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Analyst Reco.

Filters